Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01770691
Other study ID # TIPI 004
Secondary ID
Status Completed
Phase N/A
First received January 16, 2013
Last updated January 15, 2015
Start date September 2007
Est. completion date June 2009

Study information

Verified date January 2015
Source Assuta Hospital Systems
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

Stress urinary incontinence (SUI) is most prevalent among women. SUI is characterized by loss of urine from increased abdominal pressures caused by coughing, laughing, sneezing, running, lifting or walking. SUI cause women to avoid routine physical activities, thus detracting significantly from their quality of life.

The purpose of this study is to evaluate the performance of new designs of the TIPI device, a conservative, disposable, treatment for temporary management of SUI.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date June 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Females aged 18 to 60 years

- Had = 1 deliveries

- Suffering from genuine stress urinary incontinence confirmed by urodynamic testing (Urodynamic stress urinary incontinence) and normal voiding without abnormal residual urine

- Baseline PWG (no usage of TIPI device) = 6gr/8hrs

- Average reduction of urinary incontinence of at least 70% following 3 days usage of the cleared TIPI G3 device

- The patient has the ability to understand the nature of the study and give her consent by signing a written informed consent form.

- Successful experience with the use of vaginal tampons

- Willing to undergo urodynamic investigation

- Normal pap smear within past 24 months

- Patient is able and agrees to arrive to the study site area for a period of about 4-6 hours during 6-12 non consequent study days.

Exclusion Criteria:

- Patient is pregnant, or suspected to be pregnant or is planning to be pregnant during the course of the study

- Patients with present or suspected urinary infection

- Patients with present or suspected vaginal infection

- Severely atrophic vagina

- Women who did not manage to insert a vaginal tampon, for any reason, in the past

- Abnormal vaginal bleeding

- Patient is currently participating in another clinical study that may directly or indirectly affect the results of this study

- Was/is being treated for urinary incontinence by other means such as medications, surgical intervention etc. that might influence study results

- Vaginal wall prolapse of any type reaching the level of the introitus (grade 2)

- Co-morbid condition(s) that could limit the patient's ability to participate in the study, or impact the scientific integrity of the study

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
TIPI vaginal pessary
TIPI vaginal pessary G3 model, and TIPI SMD's

Locations

Country Name City State
Israel Urodynamic Unit, Assuta Medical Centers Tel Aviv

Sponsors (1)

Lead Sponsor Collaborator
Assuta Hospital Systems

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Percentage of Pad Weight Gain (PWG) Change All eligible subjects underwent a 3-day Pad period to establish baseline Average PWG. During this period, pre-weighed pads were worn for 8 hours a day and subjects were asked to perform predefined physical activities and drink a certain amount of liquid, daily. Pads were collected and weighed in the clinic to determine baseline urine leakage. Subjects then used SMDs or the cleared TIPI (G3) with pads for up to 8 hours. The average PWG tests results with the TIPI devices were compared to the average PWG 8 hrs test without the device and were presented as percentages.
The efficacy endpoint for the study was mean percent change of PWG using a certain device compared to the values obtained at the baseline period, as calculated by the following formula:
% Reduction = 1-(Device/Baseline )*100
Where, Device = the average pad weight gain (PWG) during device usage. Baseline = the average pad weight gain (PWG) during the days of baseline period.
up to 8 hours of use No
See also
  Status Clinical Trial Phase
Recruiting NCT04829357 - Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT04512053 - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence Phase 2
Active, not recruiting NCT06224335 - Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
Recruiting NCT05304312 - The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women N/A
Not yet recruiting NCT05527665 - Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
Not yet recruiting NCT04558762 - Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
Withdrawn NCT02524366 - A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT01924728 - Efficacy of Magnetic Stimulation for Stress Urinary Incontinence N/A
Completed NCT01676662 - Solace European Confirmatory Trial N/A
Unknown status NCT01455779 - Lyrette: Renewing Continence Objective and Subjective Efficacy Study N/A
Terminated NCT01029106 - Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI) N/A
Withdrawn NCT00573703 - Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence Phase 4
Completed NCT01123096 - Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence? N/A
Completed NCT00234754 - Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women N/A
Completed NCT00441454 - Retropubic vs. Transobturator Tension-free Vaginal Tape N/A
Completed NCT03985345 - Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence. N/A
Active, not recruiting NCT03671694 - Laser Vaginal Treatment for SUI N/A
Completed NCT04097288 - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Phase 1
Recruiting NCT05272644 - Efficacy of Biofeedback-Assisted Pelvic Muscle Floor Training and Electrical Stimulation on Women With Stress Urinary Incontinence N/A